Antibodies

14 Aug 2020 Prometheus Biosciences and Dr. Falk Pharma GmbH Announce Global Collaboration Agreement to Develop and Commercialize a Novel IBD Antibody
13 Aug 2020 Novo Nordisk resumes the phase 3 clinical trials investigating concizumab (anti-TFPI mAB) in haemophilia A and B with or without inhibitors
12 Aug 2020 Celleron Therapeutics enters into a license agreement with Roche to improve the lives of patients living with tenosynovial giant cell tumour
12 Aug 2020 FDA Accepts Evinacumab Biologics License Application for Priority Review as a Treatment for Patients with HoFH, an Ultra-rare Inherited Form of High Cholesterol
12 Aug 2020 KAHR Medical Announces FDA Clearance of IND Application for DSP107, anti-CD47 Candidate for the Treatment of Solid Tumors
11 Aug 2020 SAB Biotherapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of SAB-185 for the Treatment and Prevention of COVID-19
11 Aug 2020 Byondis Initiates Phase I Study of Antibody-Drug Conjugate SYD1875
11 Aug 2020 Kymab Announces Positive Phase 2a Results for KY1005 in Moderate to Severe Atopic Dermatitis
11 Aug 2020 FibroGen Announces First Patient Enrolled in Pamrevlumab Phase 3 Clinical Trial in Patients with Duchenne Muscular Dystrophy
11 Aug 2020 CheckMate -577, a Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival
11 Aug 2020 CheckMate -649, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Chemotherapy vs. Chemotherapy, Meets Primary Endpoints Demonstrating Superior Overall Survival and Progression-Free Survival in First-Line Treatment of Gastric and Esophageal Cancers
11 Aug 2020 Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for wet AMD, Reports Recent Business Progress and Second Quarter 2020 Financial Results
10 Aug 2020 AnaptysBio Reports Top-Line Data From Interim Analysis of ECLIPSE Phase 2 Clinical Trial of Etokimab in Chronic Rhinosinusitis with Nasal Polyps
10 Aug 2020 Pieris and Lilly Enter Into a Clinical Trial Collaboration to Evaluate Combination of PRS-343 With Ramucirumab and Paclitaxel in Gastric Cancer
10 Aug 2020 Genentech Provides Update on Phase III Studies of Etrolizumab in People With Moderately to Severely Active Ulcerative Colitis
08 Aug 2020 Opdivo® (nivolumab) Plus Yervoy® (ipilimumab) Demonstrates Durable Survival Benefit vs. Chemotherapy in Patients with Previously Untreated Malignant Pleural Mesothelioma
07 Aug 2020 FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review
07 Aug 2020 CStone Announces CS1001 (Anti-PD-L1 mAb) Phase III Trial Met the Primary Endpoint as First-Line Treatment in Stage IV Squamous and Non-squamous Non-Small Cell Lung Cancer and Plans to Submit a New Drug Application
07 Aug 2020 Genentech Provides Update On Phase III Study Of Tecentriq In Combination With Paclitaxel For People With Metastatic Triple-Negative Breast Cancer
07 Aug 2020 Novartis receives EC approval for new Xolair® indication to treat severe chronic rhinosinusitis with nasal polyps
06 Aug 2020 Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan (U3-1402) in Combination with TAGRISSO in EGFR-Mutated Non-Small Cell Lung Cancer
06 Aug 2020 FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
04 Aug 2020 Voyager Therapeutics Provides Update on AbbVie Vectorized Antibody Collaborations
03 Aug 2020 Innovent Announces First Patient Dosed in the Phase 1 Clinical Trial of Anti-CD47/PD-L1 Bispecific Antibody in China
03 Aug 2020 AC Immune Initiates IND-Enabling Studies for First-in-Class Antibody Targeting TDP-43 to Treat Neurodegeneration

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top